Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-06-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00116-08PMID 18591269PMCID PMC2533442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard

  2008cited by this paper
• Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method

  2008cited by this paper
• Prospective Observational Study of Candidemia in São Paulo, Brazil: Incidence Rate, Epidemiology, and Predictors of Mortality

  2007cited by this paper
• Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia

  2007influential reference
• In Vitro Susceptibility of Breakthrough Candida Bloodstream Isolates Correlates with Daily and Cumulative Doses of Fluconazole

  2006cited by this paper
• Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing

  2006cited by this paper
• Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia

  2006influential reference
• Pharmacokinetics and pharmacodynamics of antifungals.

  2006cited by this paper
• Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia

  2006cited by this paper
• Invasive candidiasis.

  2006cited by this paper
• Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

  2006cited by this paper
• Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia

  2005influential reference
• Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines.

  2005cited by this paper
• Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection

  2004cited by this paper
• Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia.

  2004cited by this paper
• In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model

  2003cited by this paper
• In Vivo Pathogenicity of Eight Medically Relevant Candida Species in an Animal Model

  2002cited by this paper
• Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

  2001cited by this paper
• Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole

  2000cited by this paper
• Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?

  2000cited by this paper
• Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

  2000cited by this paper
• Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model

  1999cited by this paper
• Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis

  1998cited by this paper
• Pharmacokinetic Studies of Fluconazole in Rabbits Characterizing Doses Which Achieve Peak Levels in Serum and Area under the Concentration-Time Curve Values Which Mimic Those of High-Dose Fluconazole in Humans

  1998cited by this paper
• Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis.

  1998cited by this paper
• Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora

  1997cited by this paper
• A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

  1994cited by this paper
• A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

  1994cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development

  2026cites this paper
• A screen to identify antifungal antagonists reveals a variety of pharmacotherapies that induce echinocandin tolerance in Candida albicans

  2025cites this paper
• A screen to identify antifungal antagonists reveals a variety of pharmacotherapies induce echinocandin tolerance in Candida albicans

  2025cites this paper
• Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections

  2024cites this paper
• Infections fongiques en réanimation

  2024cites this paper
• Clinical impact of the combination of rapid species identification and antifungal stewardship intervention in adults with candidemia.

  2023cites this paper
• Structural, optical and antifungal properties of the PMMA-ZnO nanocomposites: Potential applications in odontology

  2023cites this paper
• Phytochemical analysis of Cymbopogon flexuosus (lemongrass) oil, its antifungal activity, and role in inhibiting biofilm formation in Candida albicans MTCC854

  2022cites this paper
• Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis

  2022cites this paper
• PET Imaging of Active Invasive Fungal Infections with d-[5-11C]-Glutamine.

  2022cites this paper
• Low-Molecular Pyrazine-Based DNA Binders: Physicochemical and Antimicrobial Properties

  2022cites this paper
• Drug repurposing against Candida auris: A systematic review

  2022cites this paper
• Rapid and high-throughput testing of antifungal susceptibility using an AIEgen-based analytical system.

  2022cites this paper
• Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions

  2021cites this paper
• Structural determinants for subnanomolar inhibition of the secreted aspartic protease Sapp1p from Candida parapsilosis

  2021cites this paper
• Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future

  2021cites this paper
• Fungal infections—Background to specific fungal species

  2021cites this paper
• Drug resistance in Candida albicans isolates and related changes in the structural domain of Mdr1 protein.

  2021cites this paper
• Emerging issue of fluconazole-resistant candidemia in a tertiary care hospital of southern italy: time for antifungal stewardship program.

  2021cites this paper
• Antifungal Susceptibility Testing: A Primer for Clinicians

  2021cites this paper
• Analysis of Volatile Molecules Present in the Secretome of the Fungal Pathogen Candida glabrata

  2021cites this paper
• Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy

  2021cites this paper
• From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis

  2020cites this paper
• Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins

  2020cites this paper
• Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections

  2020cites this paper
• Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs Useful for clinicians?

  2020cites this paper
• Challenges in Antifungal Therapy in Diabetes Mellitus

  2020cites this paper
• Isothermal microcalorimetric determination of the inhibition of Candida species by antifungals

  2020cites this paper
• Antifungal Resistance Testing and Implications for Management

  2019cites this paper
• Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis

  2019cites this paper
• Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)

  2019cites this paper
• The association between fluconazole dose and MIC with mortality and persistence in candidemia

  2019cites this paper
• Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?

  2018cites this paper
• Overview of antifungal dosing in invasive candidiasis.

  2018cites this paper
• Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China

  2018cites this paper
• Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose

  2018cites this paper
• “ Deescalation ” strategy using micafungin for the treatment of systemic Candida infections : budget impact in France and Germany

  2017cites this paper
• [Role of therapeutic drug monitoring in pulmonary infections].

  2017cites this paper
• Bibliometric analysis of literature on antifungal triazole resistance: 1980 - 2015.

  2017cites this paper
• Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance.

  2017cites this paper
• Intérêt du suivi thérapeutique pharmacologique dans le cadre des infections pulmonaires

  2017cites this paper
• High order interaction analysis of SNPs in PEDF (rs12150053, rs12948385) and EPO (rs1617640) genes with clinical determinants of type 2 diabetic retinopathy patients from south India

  2017cites this paper
• The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.

  2017cites this paper
• Candida and Candidiasis

  2017cites this paper
• 156 – Systemic Antifungal Agents

  2017cites this paper
• Production of novel antifungal compounds from actinomycetes isolated from waste dump soil in Western Uganda

  2017cites this paper
• “De-escalation” strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany

  2017cites this paper
• Practical Pharmacokinetics and Pharmacodynamics

  2016cites this paper
• Suivi thérapeutique pharmacologique des antifongiques : utile ?

  2016cites this paper
• Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.

  2016cites this paper
• Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.

  2016cites this paper
• Yeasts

  2016cites this paper
• Antibiotic Dosing During Continuous Renal Replacement Therapy (CRRT)

  2016cites this paper
• Inhibitory Effect of Cratoxylum formosum Gum on Candida glabrata and Its α-mangostin Content

  2016cites this paper
• Antifungal pharmacodynamics: Latin America's perspective

  2016cites this paper
• Yeast Infections After Haematopoietic Stem Cell Transplantation

  2016cites this paper
• Time to overcome fluconazole resistant Candida isolates: Solid lipid nanoparticles as a novel antifungal drug delivery system.

  2016cites this paper
• Invasive Fungal Infections in the Era of Antifungal Resistance

  2015cites this paper
• Fluconazole Loaded Ethosomes Gel and Liposomes Gel: An Updated Review for the Treatment of Deep Fungal Skin Infection

  2015cites this paper
• In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis

  2015cites this paper
• Pharmacokinetics and optimal exposure of antifungal drugs in critically ill patients

  2015cites this paper
• How much European prescribing physicians know about invasive fungal infections management?

  2015cites this paper
• Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

  2015cites this paper
• Training should be the first step toward an antifungal stewardship program.

  2015cites this paper
• Antifungal pharmacokinetics and pharmacodynamics.

  2015cites this paper
• Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection.

  2015cites this paper
• Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

  2014cites this paper
• Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species

  2014cites this paper
• Antimicrobial agents, drug adverse reactions and interactions, and cancer.

  2014cites this paper
• Invasive Fungal Infections in the ICU: How to Approach, How to Treat

  2014cites this paper
• Fluconazole Pharmacokinetics in a Morbidly Obese, Critically Ill Patient Receiving Continuous Venovenous Hemofiltration

  2014cites this paper
• Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.

  2014cites this paper
• The oxidative stress response of the opportunistic fungal pathogen Candida glabrata.

  2014cites this paper
• Characteristics of Hospital-Acquired and Community-Onset Blood Stream Infections, South-East Austria

  2014cites this paper
• Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective

  2014cites this paper
• Support for the EUCASTand revised CLSI fluconazole clinical breakpoints by Sensititre w YeastOne w for Candida albicans : a prospective observational cohort study

  2014cites this paper
• Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed.

  2014cites this paper
• Is Timely and Appropriate Antifungal Drug Enough for Survival of Adult Cases with Candidaemia? Five-year Experience.

  2014cites this paper
• 15 Antifungal Pharmacokinetics

  2014cites this paper
• Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

  2014cites this paper
• Simultaneous Quantification of Anidulafungin and Caspofungin in Plasma by an Accurate and Simple Liquid Chromatography Tandem Mass-Spectrometric Method

  2013cites this paper
• Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.

  2013cites this paper
• Candida and candidaemia. Susceptibility and epidemiology.

  2013cites this paper
• Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

  2013cites this paper
• Fungal diagnosis: how do we do it and can we do better?

  2013cites this paper
• Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

  2013cites this paper
• Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model

  2013cites this paper
• Low but Sufficient Anidulafungin Exposure in Critically Ill Patients

  2013cites this paper
• The Evolving Role of Antifungal Susceptibility Testing

  2013cites this paper
• De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections

  2013cites this paper
• Antimicrobial dosing in acute renal replacement.

  2013cites this paper
• Mechanisms of fluconazole resistance in Candida parapsilosis clinical isolates

  2013cites this paper
• Antifungal therapy: current concepts and evidence-based management

  2013cites this paper
• Isavuconazole Pharmacodynamic Target Determination for Candida species in an In vivo 1

  2013cites this paper
• Review Fungal diagnosis: how do we do it and can we do better?

  2013cites this paper
• De la bonne utilisation des antifongiques systémiques en réanimation

  2013cites this paper
• Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

  2012cites this paper
• Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations

  2012cites this paper
• [Invasive fungal infection in critically ill patient: role of micafungin].

  2012cites this paper